Johnson & Johnson on Townhall

Watch: Big Pharma Is Having a Meltdown
Kurt Schlichter| May 07, 2021
FDA is Facing a Serious Crisis of Priorities
Rebecca Downs| April 14, 2021
A Comprehensive Cost-Benefit Analysis Of The Vaccine
Daniel J. Mitchell| April 14, 2021
Johnson & Johnson Vaccine Gets Thumbs Up from FDA Staff
Cortney O'Brien| February 24, 2021